International expert panel on the use of primary (Preoperative) systemic treatment of operable breast cancer: Review and recommendations

被引：255

作者：

Kaufmann, M

von Minckwitz, G

Smith, R

Valero, V

Gianni, L

Eiermann, W

Howell, A

Costa, SD

Beuzeboc, P

Untch, M

Blohmer, JU

Sinn, HP

Sittek, R

Souchon, R

Tulusan, AH

Volm, T

Senn, HJ

机构：

[1] Goethe Univ Frankfurt, Klin Gynakol & Geburtshilfe, D-60590 Frankfurt, Germany

[2] Univ Grosshadern, Res Cross Gynecol Hosp, Munich, Germany

[3] Charite Hosp, Berlin, Germany

[4] Heidelberg Univ, Heidelberg, Germany

[5] Gen Hosp, Hagen, Germany

[6] Gen Hosp, Bayreuth, Germany

[7] Univ Hosp, Ulm, Germany

[8] Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA

[9] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

[10] Natl Canc Inst, I-20133 Milan, Italy

[11] Christie Hosp NHS Trust, Manchester, Lancs, England

[12] Ctr Tumor Prevent, St Gallen, Switzerland

[13] Inst Curie, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 13期

关键词：

D O I：

10.1200/JCO.2003.01.136

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Primary systemic therapy (PST) represents the standard of care in patients with locally advanced breast cancer. In addition, there is increasing information on PST in operable breast disease that supports the use of PST in routine practice. However, current regimens and techniques vary. To address this concern, a group of representatives from breast cancer clinical research groups in France, Germany, Italy, the United Kingdom, and the United States reviewed all available data on prospective randomized trials in this setting. Recommendations are made regarding terminology, indications, regimen, diagnosis before treatment, monitoring of efficacy, tumor localization, surgery, pathologic evaluation, and postoperative treatment. (C) 2003 by American Society of Clinical Oncology.

引用

页码：2600 / 2608

页数：9

共 55 条

[1]

Abe O, 1998, LANCET, V352, P930

[2] Identification of high risk breast-cancer patients by gene expression profiling [J].

Ahr, A ;

Karn, T ;

Solbach, C ;

Seiter, T ;

Strebhardt, K ;

Holtrich, U ;

Kaufmann, M .

LANCET, 2002, 359 (9301) :131-132

[3] PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST-CANCER [J].

ANDERSON, EDC ;

FORREST, APM ;

HAWKINS, RA ;

ANDERSON, TJ ;

LEONARD, RCF ;

CHETTY, U .

BRITISH JOURNAL OF CANCER, 1991, 63 (04) :561-566

[4]

[Anonymous], 1996, Lancet, V348, P1189

[5]

[Anonymous], [No title captured]

[6] Management of breast cancer during pregnancy using a standardized protocol [J].

Berry, DL ;

Theriault, RL ;

Holmes, FA ;

Parisi, VM ;

Booser, DJ ;

Singletary, SE ;

Buzdar, AU ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :855-861

[7] PRIMARY CHEMOTHERAPY TO AVOID MASTECTOMY IN TUMORS WITH DIAMETERS OF 3 CENTIMETERS OR MORE [J].

BONADONNA, G ;

VERONESI, U ;

BRAMBILLA, C ;

FERRARI, L ;

LUINI, A ;

GRECO, M ;

BARTOLI, C ;

DEYOLDI, GC ;

ZUCALI, R ;

RILKE, F ;

ANDREOLA, S ;

SILVESTRINI, R ;

DIFRONZO, G ;

VALAGUSSA, P .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (19) :1539-1545

[8] Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute [J].

Bonadonna, G ;

Valagussa, P ;

Brambilla, C ;

Ferrari, L ;

Moliterni, A ;

Terenziani, M ;

Zambetti, M .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :93-100

[9] Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer [J].

Buzdar, AU ;

Singletary, SE ;

Theriault, RL ;

Booser, DJ ;

Valero, V ;

Ibrahim, N ;

Smith, TL ;

Asmar, L ;

Frye, D ;

Manuel, N ;

Kau, SW ;

McNeese, M ;

Strom, E ;

Hunt, K ;

Ames, F ;

Hortobagyi, GN .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3412-3417

[10]

CALAIS G, 1994, CANCER, V74, P1283, DOI 10.1002/1097-0142(19940815)74:4<1283::AID-CNCR2820740417>3.0.CO

← 1 2 3 4 5 6 →